European continuous manufacturing tech could boost Tunisia's pharma sector

A European consortium has successfully piloted a new technology that could reshape pharmaceutical manufacturing. The PIPAC consortium, comprising De Dietrich, Alysophil, Bruker, and Novalix, announced the completion of its pilot program for a continuous production platform for active pharmaceutical ingredients (APIs).

This innovative European technology aims to break away from centralized production chains, fostering more flexible and localized manufacturing closer to markets. It integrates flow chemistry, real-time analytical monitoring, and an AI-driven control system. This approach allows for continuous production and monitoring of pharmaceutical compounds, offering potential gains in flexibility, quality, and speed compared to traditional batch processes.

The consortium demonstrated the platform's capabilities by continuously producing fentanyl, a highly regulated active ingredient chosen for its manufacturing complexity. This development arrives as governments and industries worldwide seek to diversify drug supply sources and bolster pharmaceutical supply chain resilience following recent logistical disruptions and health crises.

For Tunisia, with its growing pharmaceutical sector and focus on health sovereignty, this technology could pave the way for more adaptable production units catering to local market needs. The presence of Novalix, a consortium member specializing in contract drug discovery research, in Tunisia since 2018 further supports this dynamic. The consortium believes these new platforms can enhance manufacturing site flexibility and supply security.

Following the pilot program's validation, PIPAC is preparing for industrial deployment and eventual commercialization of these next-generation API production platforms. This technological evolution presents a significant opportunity for Tunisia to strengthen its industrial capacity, diversify its active ingredient sources, and solidify its position in the pharmaceutical value chain.